Literature DB >> 12854116

L-Erythro-methoxamine is more potent than phenylephrine in effecting contraction of internal anal sphincter in vitro.

O M Jones1, J M Thompson, A F Brading, N J McC Mortensen.   

Abstract

BACKGROUND: Topical phenylephrine has been shown to increase resting anal canal pressure in normal and incontinent individuals. However, high concentrations of gel (10-40 per cent) are required that may cause local side-effects. The aim of this study was to determine whether methoxamine, another alpha-1-adrenoceptor agonist, might be a more potent alternative to phenylephrine.
METHODS: Porcine internal anal sphincter (IAS) tissue was cut into strips, suspended in a superfusion organ bath and allowed to equilibrate. Strips were subjected to each drug under test for 20 s, sufficient to obtain stable tone. Phenylephrine, methoxamine (1 : 1 : 1 : 1 ratio of its four isomers) and each of the individual isomers of methoxamine were evaluated in turn.
RESULTS: In vitro, methoxamine racemate and phenylephrine were similarly potent in causing contraction of IAS strips (mean(s.e.m.) dose giving half maximal effect (EC(50)) at 74.7(16.5) versus 58.3(13.4) micro M respectively; P = 0.443). However, one of the methoxamine isomers, L-erythro-methoxamine (EC(50) 17.6(3.7) micro M), was significantly more potent than the other three isomers, methoxamine racemate and phenylephrine (P = 0.002).
CONCLUSION: L-Erythro-methoxamine is four times more potent than phenylephrine and is a possible treatment for incontinence. Trials are under way to examine the efficacy of L-erythro-methoxamine in vivo. Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12854116     DOI: 10.1002/bjs.4120

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Investigation of the distribution and function of alpha-adrenoceptors in the sheep isolated internal anal sphincter.

Authors:  S J Rayment; T Eames; J A D Simpson; M R Dashwood; Y Henry; H Gruss; A G Acheson; J H Scholefield; V G Wilson
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Towards safer treatments for benign anorectal disease: the pharmacological manipulation of the internal anal sphincter.

Authors:  Oliver M Jones
Journal:  Ann R Coll Surg Engl       Date:  2007-09       Impact factor: 1.891

3.  Libertas: a phase II placebo-controlled study of NRL001 in patients with faecal incontinence showed an unexpected and sustained placebo response.

Authors:  L Siproudhis; W Graf; A Emmanuel; D Walker; R Ng Kwet Shing; C Pediconi; J Pilot; S Wexner; J Scholefield
Journal:  Int J Colorectal Dis       Date:  2016-04-13       Impact factor: 2.571

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.